Association of alkaline phosphatase with clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): results from COU-AA-302

被引：0
|
作者：
Mainwaring, P. [1 ]
Yu, E. Y. [2 ]
Londhe, A. [3 ]
Van Poppel, H. [4 ]
Rathkopf, D. E. [5 ,6 ]
Smith, M. R. [7 ,8 ]
Souza, P. [9 ]
Griffin, T. W. [10 ]
Ryan, C. J. [11 ]
机构：
[1] Hematol & Oncol Clin Australia, Brisbane, Qld, Australia
[2] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[3] Janssen Res & Dev LLC, Raritan, NJ USA
[4] Katholieke Univ Leuven Hosp, Louvain, Belgium
[5] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[6] Weill Cornell Med Coll, New York, NY USA
[7] Harvard Univ, Sch Med, Boston, MA USA
[8] Massachusetts Gen Hosp, Boston, MA 02114 USA
[9] Univ Western Sydney, Sch Med, Sydney, NSW, Australia
[10] Janssen Res & Dev, Los Angeles, CA USA
[11] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
来源：
BJU INTERNATIONAL | 2014年 / 113卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
41
引用
收藏
页码：21 / 21
页数：1
相关论文
共 50 条
  • [31] Enzalutamide: A Review of Its Use in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
    Keating, Gillian M.
    DRUGS & AGING, 2015, 32 (03) : 243 - 249
  • [32] Response to androgen signaling (AS)-directed therapy after treatment with abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Post hoc analysis of study COU-AA-302
    Smith, Matthew R.
    Matheny, Shannon
    Saad, Fred
    Rathkopf, Dana E.
    Mulders, Peter F. A.
    De Bono, Johann Sebastian
    Small, Eric Jay
    Shore, Neal D.
    Fizazi, Karim
    Kheoh, Thian San
    Li, Jinhui
    Todd, Mary Beth
    Griffin, Thomas W.
    Yu, Margaret K.
    Ryan, Charles J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [33] Abiraterone acetate (AA) with or without cabazitaxel (CBZ) in treatment of chemotherapy naive metastatic castration-resistant prostate cancer (mCRPC)
    Slovin, Susan F.
    Knudsen, Karen E.
    Halabi, Susan
    Fleming, Mark T.
    Molina, Ana M.
    Wolf, Steven Paul
    de Leeuw, Renee
    Fernandez, Celina
    Kang, Praneet
    Southwell, Traci
    Jones, Carol L.
    Fernandez, Escarleth
    Kelly, William Kevin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [34] Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302)
    Rathkopf, Dana E.
    Smith, Matthew R.
    de Bono, Johann S.
    Logothetis, Christopher J.
    Shore, Neal D.
    de Souza, Paul
    Fizazi, Karim
    Mulders, Peter F. A.
    Mainwaring, Paul
    Hainsworth, John D.
    Beer, Tomasz M.
    North, Scott
    Fradet, Yves
    Van Poppel, Hendrik
    Carles, Joan
    Flaig, Thomas W.
    Efstathiou, Eleni
    Yu, Evan Y.
    Higano, Celestia S.
    Taplin, Mary-Ellen
    Griffin, Thomas W.
    Todd, Mary B.
    Yu, Margaret K.
    Park, Youn C.
    Kheoh, Thian
    Small, Eric J.
    Scher, Howard I.
    Molina, Arturo
    Ryan, Charles J.
    Saad, Fred
    EUROPEAN UROLOGY, 2014, 66 (05) : 815 - 825
  • [35] Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302
    Smith, Matthew R.
    Saad, Fred
    Rathkopf, Dana E.
    Mulders, Peter F. A.
    de Bono, Johann S.
    Small, Eric J.
    Shore, Neal D.
    Fizazi, Karim
    Thian Kheoh
    Li, Jinhui
    De Porre, Peter
    Todd, Mary B.
    Yu, Margaret K.
    Ryan, Charles J.
    EUROPEAN UROLOGY, 2017, 72 (01) : 10 - 13
  • [36] Prognostic index for progression-free survival in metastatic castration-resistant prostate cancer patients without previous chemotherapy: An analysis of the COU-AA-302 abiraterone acetate study
    Ryan, C. J.
    Kheoh, T.
    Molina, A.
    Carles, J.
    Efstathiou, E.
    Kantoff, P. W.
    Mulders, P. F. A.
    Saad, F.
    Griffin, T.
    Chi, K. N.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S683 - S684
  • [37] Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate
    Tagawa, Scott T.
    Ramaswamy, Krishnan
    Huang, Ahong
    Mardekian, Jack
    Schultz, Neil M.
    Wang, Li
    Sandin, Rickard
    Lechpammer, Stanislav
    George, Daniel J.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2021, 24 (04) : 1032 - 1040
  • [38] A prognostic model for stratifying clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetate
    Khalaf, Daniel Joseph
    Aviles, Claudia M.
    Azad, Arun A.
    Sunderland, Katherine
    Todenhofer, Tilman
    Eigl, Berhard J.
    Finch, Daygen
    Le, Lyly
    Atwell, Andrew
    Keith, Bruce
    Kollmannsberger, Christian
    Chi, Kim. N.
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2018, 12 (02): : E47 - E52
  • [39] Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate
    Scott T. Tagawa
    Krishnan Ramaswamy
    Ahong Huang
    Jack Mardekian
    Neil M. Schultz
    Li Wang
    Rickard Sandin
    Stanislav Lechpammer
    Daniel J. George
    Prostate Cancer and Prostatic Diseases, 2021, 24 : 1032 - 1040
  • [40] Subgroup analyses of Japanese patients from the PREVAIL trial of enzalutamide (ENZA) in patients with chemotherapy-naive, metastatic castration-resistant prostate cancer (mCRPC).
    Kimura, Go
    Yonese, Junji
    Fukagai, Takashi
    Kamba, Tomomi
    Nishimura, Kazuo
    Nozawa, Masahiro
    Mansbach, Harry H.
    Phung, De
    Beer, Tomasz M.
    Tombal, Bertrand F.
    Ueda, Takeshi
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
12345